ANTI-AMYLOID THERAPIES: WHERE ARE WE NOW?

Aimee L. Pierce, MD & Joshua D. Grill, PhD

The “amyloid hypothesis” posits that the abnormal accumulation of amyloid-beta in the brain is the first step in a cascade of biological changes leading to Alzheimer’s disease. The amyloid hypothesis remains a dominant theme on the international Alzheimer’s disease research agenda, especially in drug development. Of the over 60 therapies currently being tested in human clinical trials as potential disease-slowing treatments or preventions for Alzheimer’s disease, more than half target amyloid in some manner.

But the recent news for anti-amyloid therapies has been discouraging. Bapineuzumab, the first anti-amyloid treatment to complete phase 3 trials (the last phase before FDA approval) failed to slow disease progression when tested in patients with mild-to-moderate dementia. Solanezumab, the second anti-amyloid treatment to complete phase 3 trials similarly failed to demonstrate efficacy in mild-to-moderate dementia, as well as in mild dementia. Do these negative results mean we should abandon the amyloid hypothesis? Certainly not.

Other anti-amyloid therapies have generated great enthusiasm in early phase trials because of an ability to remove amyloid from the brain at unprecedented levels, suggesting that all anti-amyloid therapies are not created equal. Additionally, many researchers believe that any anti-amyloid therapy will be most effective if started as early in the disease process as possible. This makes prevention studies in asymptomatic older adults, like the A4 Study and the soon-to-launch EARLY study, all the more critical in the larger Alzheimer’s disease research agenda.

The world urgently needs new treatments to slow, stop, or prevent Alzheimer’s disease and researchers desperately want to discover such treatments. Unfortunately, science takes time, resources, and partnership with large numbers of volunteer participants. The next few years will reveal several important results that will shed light on the validity of the amyloid hypothesis. While UCI MIND remains at the forefront of these and other studies that examine anti-amyloid therapies, we will also perform studies on non-amyloid therapies, some of which are already underway. And we will not rest until we transform the care of Alzheimer’s disease. To learn more about clinical trials at UCI MIND, please contact our research coordinator at 949.824.0008 or research@mind.uci.edu.

Promising Junior Investigators Awarded Prestigious Grants

UCI MIND congratulates five postdoctoral fellows in the laboratories of Drs. Frank LaFerla, Masashi Kitazawa, and Kim Green, who were recently awarded prestigious grants. Many of the passionate young researchers at UCI MIND are driven by personal experiences to find improved treatments, preventions, and cures for Alzheimer’s disease and related dementias. Dr. Stefania Forner, an Alzheimer’s Association Research Fellowship (AARF) recipient states, “We are made of memories, and the thought of such a disease capable of disassociating us from the people we love and the world made me want to be a part of a team of researchers who are fighting not only for a better understanding of the disease, but for a cure.” Dr. Forner’s project investigates the relationship between brain cells’ actin cytoskeletons and the loss of synapses (connections between brain cells) in Alzheimer’s disease. Dr. Lindsay Hohsfield, another AARF recipient and young investigator who has been personally impacted by Alzheimer’s disease, will test a drug regimen hypothesized to regulate microglia, immune cells believed to be chronically over-activated in Alzheimer’s disease.

From left: Drs. Heng-Wei Hsu, Siok Lam Lim, Alessandra Martini, Lindsay Hohsfield, and Stefania Forner
Dear Friends,

As 2016 came to a close, we communicated to you that we were at a critical but hopeful juncture in the history of Alzheimer’s disease research. Several exciting studies were on the horizon and we anticipated a significant increase in National Institutes of Health (NIH) funding for Alzheimer’s disease research.

As 2017 begins, this hope has given way to uncertainty. With a new administration and no approved federal budget as of February 1, researchers are understandably nervous. In regard to NIH funding, it is unclear what actions will be taken by President Trump and his nominee to lead the Department of Health and Human Services, Representative Tom Price (R-GA). Rep. Price is a known budget hawk, but when asked during his confirmation hearings about the very low levels of Alzheimer’s disease research funding, relative to the large numbers of afflicted Americans, he responded that it is “absolutely imperative” to ensure a better proportionality of resources.

The truth is, we don’t yet know what to expect from the new administration or the incoming Secretary about the NIH budget or funding for Alzheimer’s disease research. What we do know is that greater investment in Alzheimer’s disease research is needed now more than ever. We will continue to pursue every opportunity to see research accelerate at UCI MIND—be it through NIH funding, foundation grants, or philanthropy. Substantial work remains to be done to change the way we treat Alzheimer’s disease, and we will work tirelessly until we achieve a world without Alzheimer’s disease and other dementias—a world where memories last a lifetime. We hope you will join us in this commitment.

The 23rd UCI Distinguished Lecture Series on Brain, Learning, and Memory hosted by UCI MIND, UCI Ayala School of Biological Sciences, and UCI Center for the Neurobiology of Learning and Memory was held on February 7 at the Irvine Barclay Theatre. Dr. Ruth Benca, UCI MIND faculty member and Professor and Chair of Psychiatry and Human Behavior, delivered a lecture on sleep and brain health to over 850 community members, the largest attendance for this series to date. Dr. Benca’s engaging presentation first addressed why humans need sleep and some of the common disorders that interfere with the critical sleep process. She then discussed what sleep tells us about the brain, including the possible link between sleep and Alzheimer’s disease. She noted more research is needed to understand this relationship, including whether amyloid-beta protein is cleared from the brain during sleep and whether treating sleep disorders may reduce the risk for or slow Alzheimer’s disease. Visit our YouTube page to view the full lecture: www.youtube.com/user/UCIMIND

What Can We Learn from the Sleeping Brain?

The 23rd UCI Distinguished Lecture Series on Brain, Learning, and Memory hosted by UCI MIND, UCI Ayala School of Biological Sciences, and UCI Center for the Neurobiology of Learning and Memory was held on February 7 at the Irvine Barclay Theatre. Dr. Ruth Benca, UCI MIND faculty member and Professor and Chair of Psychiatry and Human Behavior, delivered a lecture on sleep and brain health to over 850 community members, the largest attendance for this series to date. Dr. Benca’s engaging presentation first addressed why humans need sleep and some of the common disorders that interfere with the critical sleep process. She then discussed what sleep tells us about the brain, including the possible link between sleep and Alzheimer’s disease. She noted more research is needed to understand this relationship, including whether amyloid-beta protein is cleared from the brain during sleep and whether treating sleep disorders may reduce the risk for or slow Alzheimer’s disease. Visit our YouTube page to view the full lecture: www.youtube.com/user/UCIMIND

Down Syndrome and Alzheimer’s Disease Conference

On January 21, over 150 health care professionals and family members of individuals with Down syndrome attended an educational conference hosted by Alzheimer’s Orange County, Medical, Scientific, and Practical Advances in Down Syndrome and Alzheimer’s Disease. Esteemed UCI MIND researcher, clinician, and director of the Down Syndrome Program, Dr. Ira T. Lott, presented current research on the risk factors, diagnosis, and treatment of individuals with Down syndrome and Alzheimer’s disease. His lecture was followed by moving stories from a panel of caregivers moderated by manager of the Down Syndrome Program, Eric Doran. Conference attendees were connected with valuable community resources, including Down Syndrome Association of Orange County, Regional Center of Orange County, Caregiver Support Groups at Alzheimer’s OC, and Dr. Lott’s Down Syndrome Program at UCI. If you would like to learn more about these resources and more, please contact Eric Doran at 714.456.8443 or edoran@uci.edu.
Holiday Appreciation Reception Honoring Research Volunteers

On December 14, UCI MIND hosted a holiday appreciation reception honoring the most important members of our research team, participants and their study partners. Currently, there are 300 volunteers enrolled in our Longitudinal Study, which follows healthy people with and without memory problems annually until the end of life. More than 40 others are involved in clinical trials of promising new therapies. Through their commitment to research, our volunteers help us understand the differences between people who develop cognitive problems leading to Alzheimer’s disease and those who do not, changes in biological markers that could lead to earlier diagnosis and targets for new treatments, and the safety and efficacy of potential therapies. If you or someone you know would like to learn more about the Longitudinal Study and other research participation opportunities, please contact our research coordinator at 949.824.0008 or research@mind.uci.edu.

A DECEMBER TO REMEMBER

Over 300 loyal friends and supporters of UCI MIND launched the holiday season with a December to Remember gala at the Balboa Bay Resort on December 3. The gala, led by co-chairs Roger and Lucy Lisabeth, honored distinguished faculty member, Dr. Ira T. Lott, community leaders, Burton and Linda Young, and UCI alumna, Elsa Ramon.

The event, recognized by the Los Angeles Times-Daily Pilot and the Orange County Business Journal, was the most successful to date, raising $375,000 to support Alzheimer’s disease research at UCI. UCI MIND extends sincere gratitude to the planning committee, underwriters, and sponsors who helped make the event possible.

Please save the date for the next UCI MIND gala on December 2, 2017, at the Balboa Bay Resort, and contact Linda Scheck for sponsorship opportunities: 949.824.3251 or lscheck@uci.edu.

2016 GALA SPONSORS

- Alzheimer’s Orange County
- The Beaumont Family in Honor of Dr. Jacque DuPont
- Tim and Steph Busch
- Caring Companions at Home
- The Chou Family in Memory of Doris Chou
- The Crean Foundation
- Elite OC Productions
- Irvine Cottages
- Roger and Lucy Lisabeth
- The Friends of Roger and Lucy Lisabeth
- Monster Loans
- Robert and Virginia Naeve in Memory of Helen Simpson
- San Clemente Villas by the Sea
- Silverado
- Sperry Commercial
- Sperry Equities
- Wells Fargo

Charitable Bequest

Philanthropy accelerates research and many individuals choose to include philanthropic research support among their final gifts. A bequest, or will, to support research at UCI MIND creates a legacy in your name that funds ongoing research to find answers to the neurological disorders that disrupt so many lives today. The sample language below can be used by you and your legal counsel to name UCI MIND as a beneficiary:

“I give to the University of California, Irvine Foundation, (tax id # 95-2540117) located in Irvine, California (description of gift: i.e. percentage of estate, specific dollar amount etc.), This gift shall be used to benefit research at UC Irvine’s Institute for Memory Impairments and Neurological Disorders, UCI MIND.”

Once your estate documents are complete, contact Roland Ho, Senior Executive Director of Planned Giving, at 949.824.6454 or roland.ho@uci.edu. You will be invited to become a member of the University’s Legacy Society. To learn more, contact Linda Scheck, Director of Development at 949.824.3251 or lscheck@uci.edu.
MIND MATTERS is a publication of the UCI Institute for Memory Impairments and Neurological Disorders in collaboration with the Alzheimer’s Disease Research Center (ADRC) and the California Alzheimer’s Disease Centers (CADC). The ADRC is funded by a grant from the National Institute on Aging and supports and promotes interdisciplinary research on Alzheimer’s disease. The CADC is funded by the California Department of Public Health. The CADC provides expert clinical assessments and diagnosis of memory complaints related to Alzheimer’s disease and other dementias.

EDITORS:
Joshua Grill, PhD & Chelsea Cox, MPH, MSW

Follow us on Facebook @UCIrvineMIND
Follow us on Twitter @UCIMIND

28th Annual Southern California Alzheimer’s Disease Research Conference

The Elephant in the Room
Sensitive Subjects in Dementia Care

Friday, September 22, 2017
7:30 AM - 3:30 PM
Irvine Marriott Hotel

Exhibitor Information:
kleinkm@uci.edu
949.824.9475

Registration Information:
adriana.bakhoum@alzoc.org
949.757.3721